The HSPG2 association was replicated in a refined sample from the CATIE trial, consisting of 179 schizophrenia patients of European ethnicity (Greenbaum et al., 2012), as well as a sample of Jewish Israeli schizophrenia patients (Greenbaum et al., 2012). The gene discussed is HSPG2; the disease is schizophrenia.